Dr. Hahn is Senior Vice President of Global Manufacturing Operations with responsibility for production sites in the U.S. and Europe. He joined Novavax as Senior Vice President, Manufacturing and Process Development in June 2011. Dr. Hahn has 23 years of commercial vaccine and antibody manufacturing experience and a proven track record with clinical and commercial products, process innovation, technology transfer, facility start-up, GMP compliance, and regulatory inspections. Prior to joining Novavax, he was Vice President of Antibody Manufacturing and later Vice President of Vaccine Manufacturing at MedImmune, LLC, with responsibilities for sites in the U.S. and Europe. Prior to MedImmune, Dr. Hahn spent more than 15 years in vaccine manufacturing with Merck & Co. He received his Doctorate and Master of Science degrees in Chemical Engineering from Stanford University and his Bachelor of Science degree in Chemical Engineering from Lehigh University. 

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.